249 related articles for article (PubMed ID: 34953200)
1. Targeting brain metastases in breast cancer.
Corti C; Antonarelli G; Criscitiello C; Lin NU; Carey LA; Cortés J; Poortmans P; Curigliano G
Cancer Treat Rev; 2022 Feb; 103():102324. PubMed ID: 34953200
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options for HER2-positive breast cancer patients with brain metastases.
Galanti D; Inno A; La Vecchia M; Borsellino N; Incorvaia L; Russo A; Gori S
Crit Rev Oncol Hematol; 2021 May; 161():103329. PubMed ID: 33862249
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.
Giordano G; Griguolo G; Landriscina M; Meattini I; Carbone F; Leone A; Del Re M; Fogli S; Danesi R; Colamaria A; Dieci MV
Crit Rev Oncol Hematol; 2023 Dec; 192():104185. PubMed ID: 37863404
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases of breast cancer.
Melisko ME; Kunwar S; Prados M; Berger MS; Park JW
Expert Rev Anticancer Ther; 2005 Apr; 5(2):253-68. PubMed ID: 15877523
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Bachelot T; Bailleux C; Darlix A; Jacot W
Bull Cancer; 2021 Dec; 108(11S):11S26-11S34. PubMed ID: 34969513
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
8. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
10. CNS complications of breast cancer: current and emerging treatment options.
Kaal EC; Vecht CJ
CNS Drugs; 2007; 21(7):559-79. PubMed ID: 17579499
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy of Central Nervous System Metastases of Breast Cancer.
Leone JP; Lin NU
Curr Oncol Rep; 2019 Apr; 21(6):49. PubMed ID: 30957209
[TBL] [Abstract][Full Text] [Related]
12. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for patients with advanced colorectal cancer and symptomatic brain metastases.
Tokoro T; Okuno K; Hida JC; Ueda K; Yoshifuji T; Daito K; Sugiura F
Clin Colorectal Cancer; 2014 Dec; 13(4):226-31. PubMed ID: 25442813
[TBL] [Abstract][Full Text] [Related]
15. Management of brain metastases according to molecular subtypes.
Soffietti R; Ahluwalia M; Lin N; Rudà R
Nat Rev Neurol; 2020 Oct; 16(10):557-574. PubMed ID: 32873927
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for brain metastases.
Venur VA; Karivedu V; Ahluwalia MS
Handb Clin Neurol; 2018; 149():137-153. PubMed ID: 29307351
[TBL] [Abstract][Full Text] [Related]
17. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?
Fontanella C; De Carlo E; Cinausero M; Pelizzari G; Venuti I; Puglisi F
Cancer Treat Rev; 2016 May; 46():80-8. PubMed ID: 27218867
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives.
Passalacqua MI; Ciappina G; Di Pietro M; Spagnolo CC; Squeri A; Granata B; Muscolino P; Santarpia M
Transl Cancer Res; 2023 Nov; 12(11):3179-3197. PubMed ID: 38130295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
